Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
April 08 2009 - 8:22AM
PR Newswire (US)
BALTIMORE, April 8 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
engaged in the development of advanced preclinical platforms and
tumor specific data to enhance the value of oncology drugs, has
established a UK subsidiary, Champions Biotechnology UK Ltd.
(CBUK), to expand its personalized oncology business. Guy Malchi
has been appointed General Manager of the UK subsidiary, which will
also have a branch in Israel. "We have been experiencing an
increase in activity in all of our business, particularly in our
personalized oncology service. Significantly, much of the increased
activity in our personalized oncology business is from leading
oncologists in Europe as they recognize the enhancement to their
practice that is available by utilizing Champions' services.
Champions Biotechnology UK Ltd. will enable our services to be
accessible to many more physicians in Europe and beyond. The
growing trend of medical tourism in Israel has prompted us to
establish a branch in Israel to offer our services there as well,"
said Doug Burkett, PhD, President of Champions Biotechnology, Inc.
Dr. Burkett continued, "I am delighted to welcome Guy Malchi on
board as he transitions from consultant to take on the leadership
role for CBUK. He will also lead our corporate development efforts,
which are focused on in-licensing and co-development of oncology
drug candidates that have proven successful in our Biomerk
Tumorgraft(TM) platform. Guy's expertise in strategy implementation
and business development are a valuable benefit to Champions." "I
am thrilled to join Champions Biotechnology to help it realize its
high potential," said Mr. Malchi. "I was drawn to the unique
interaction between personalized medicine and drug development, and
I look forward to contributing to the firm's success." Guy Malchi,
MBA brings more than twelve years of leadership and management
experience within the bio-pharma industry. Mr. Malchi previously
served as Chief Executive Officer for Optimata Ltd., a development
stage biopharmaceutical company focused on developing biosimulation
technologies that predict cancer patients' response to treatment.
Prior to that, Mr. Malchi was based in London with Tefen Ltd.
(Tel-Aviv stock exchange: TEFN), an international management
consulting firm where he served as the founding partner of Tefen's
successful European life science practice. Mr. Malchi received a
bachelor's degree in Industrial Engineering from Tel-Aviv
University and an executive master's degree in Business
Administration from London Business School. For more news and
information on Champions Biotechnology, Inc., please visit
http://www.irgnews.com/coi/CSBR where you can find the President's
video, a fact sheet on the company, investor presentations, and
more. About Champions Biotechnology, Inc. Champions Biotechnology,
Inc. is engaged in the development of advanced preclinical
platforms and predictive tumor specific data to enhance and
accelerate the value of oncology drugs. The Company was co-founded
by David Sidransky, M.D. who with Manuel Hidalgo, M.D., Ph.D.
developed the Company's Preclinical Platform; a novel approach
based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting
engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves
the biological characteristics of the original human tumor. Early
studies suggest that these Tumorgrafts closely reflect human cancer
biology and their response to drugs is predictive of clinical
outcomes in cancer patients. Champions Biotechnology leverages its
preclinical platform to evaluate drug candidates and to develop a
portfolio of novel therapeutic candidates. As drugs progress
through preclinical development, the Company intends to sell,
partner or license them to pharmaceutical and/or biotechnology
companies, as appropriate. The Company also offers its predictive
preclinical platform and tumor specific data to physicians for
personalized patient care and to Companies for evaluation of
oncology drugs in models that integrate prognostic testing with
biomarker discovery. Champions Biotechnology is dedicated to
enhancing preclinical development tools, accelerating development
and valuation of oncology drugs, and advancing personalized
treatment with a goal to improve the lives of cancer patients
globally. This press release contains "forward-looking statements"
(within the meaning of the Private Securities Litigation Act of
1995) that inherently involve risk and uncertainties. Champions
Biotechnology generally uses words such as "believe," "may,"
"could," "will," "intend," "expect," "anticipate," "plan," and
similar expressions to identify forward-looking statements. One
should not place undue reliance on these forward-looking
statements. The Company's actual results could differ materially
from those anticipated in the forward-looking statements for many
unforeseen factors. See Champions Biotechnology's Form 10-KSB for
the fiscal year ended April 30, 2008 for a discussion of such
risks, uncertainties and other factors. Although the Company
believes the expectations reflected in the forward-looking
statements are reasonable, they relate only to events as of the
date on which the statements are made, and Champions
Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not
intend to update any of the forward-looking statements after the
date of this press release to conform these statements to actual
results or to changes in Champions Biotechnology's expectations,
except as required by law. CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE:
http://www.championsbiotechnology.com/ DATASOURCE: Champions
Biotechnology, Inc. CONTACT: James Carbonara, Susan Morgenbesser or
Janet Vasquez, +1-212-825-3210, all of The Investor Relations
Group, Inc. for Champions Biotechnology Web Site:
http://www.championsbiotechnology.com/
Copyright